Upstream Bio Inc
NASDAQ:UPB
Upstream Bio Inc
Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The company is headquartered in Waltham, Massachusetts and currently employs 52 full-time employees. The company went IPO on 2024-10-11. The firm is developing verekitug, the only known antagonist in development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. TSLP is a member of a class of epithelial cytokines, also including IL-25 and IL-33, referred to as alarmins. TSLP is primarily produced by epithelial cells, especially in the lung, gastrointestinal tract and skin. The firm has advanced this highly potent monoclonal antibody into separate Phase II trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) and plans to initiate development of chronic obstructive pulmonary disease (COPD).
Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The company is headquartered in Waltham, Massachusetts and currently employs 52 full-time employees. The company went IPO on 2024-10-11. The firm is developing verekitug, the only known antagonist in development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. TSLP is a member of a class of epithelial cytokines, also including IL-25 and IL-33, referred to as alarmins. TSLP is primarily produced by epithelial cells, especially in the lung, gastrointestinal tract and skin. The firm has advanced this highly potent monoclonal antibody into separate Phase II trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) and plans to initiate development of chronic obstructive pulmonary disease (COPD).
